Want to see RANI full AI Analyst Report?
Total Valuation
Rani Therapeutics Holdings has a market cap or net worth of $120.16M. The enterprise value is $101.03.
Market Cap$120.16M
Enterprise Value$101.03
Share Statistics
Rani Therapeutics Holdings has 115,424,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding115,424,960
Owned by Insiders24.07%
Owned by Institutions30.58%
Financial Efficiency
Rani Therapeutics Holdings’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -80.59%.
Return on Equity (ROE)-0.90
Return on Assets (ROA)-0.51
Return on Invested Capital (ROIC)-80.59%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee23.33K
Profits Per Employee-423.90K
Employee Count70
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rani Therapeutics Holdings is ―. Rani Therapeutics Holdings’s PEG ratio is 0.05.
PE Ratio―
PS Ratio54.68
PB Ratio2.70
Price to Fair Value2.70
Price to FCF-4.75
Price to Operating Cash Flow-7.95
PEG Ratio0.05
Income Statement
In the last 12 months, Rani Therapeutics Holdings had revenue of 1.63M and earned -29.67M in profits. Earnings per share was -0.45.
Revenue1.63M
Gross Profit733.00K
Operating Income-38.31M
Pretax Income-40.95M
Net Income-29.67M
EBITDA-37.16M
Earnings Per Share (EPS)-0.45
Cash Flow
In the last 12 months, operating cash flow was -20.29M and capital expenditures -47.00K, giving a free cash flow of -20.34M billion.
Operating Cash Flow-20.29M
Free Cash Flow-20.34M
Free Cash Flow per Share-0.18
Dividends & Yields
Rani Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.25
52-Week Price Change72.40%
50-Day Moving Average0.81
200-Day Moving Average1.04
Relative Strength Index (RSI)54.09
Average Volume (3m)618.83K
Important Dates
Rani Therapeutics Holdings upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Rani Therapeutics Holdings as a current ratio of 4.21, with Debt / Equity ratio of 9.05%
Current Ratio4.21
Quick Ratio4.21
Debt to Market Cap0.03
Net Debt to EBITDA0.38
Interest Coverage Ratio-13.25
Taxes
In the past 12 months, Rani Therapeutics Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Rani Therapeutics Holdings EV to EBITDA ratio is -2.02, with an EV/FCF ratio of -3.99.
EV to Sales45.92
EV to EBITDA-2.02
EV to Free Cash Flow-3.99
EV to Operating Cash Flow-4.01
Balance Sheet
Rani Therapeutics Holdings has $53.39M in cash and marketable securities with $3.55M in debt, giving a net cash position of $49.84M billion.
Cash & Marketable Securities$53.39M
Total Debt$3.55M
Net Cash$49.84M
Net Cash Per Share$0.43
Tangible Book Value Per Share$0.63
Margins
Gross margin is 96.70%, with operating margin of -2345.99%, and net profit margin of -1817.09%.
Gross Margin96.70%
Operating Margin-2345.99%
Pretax Margin-2507.65%
Net Profit Margin-1817.09%
EBITDA Margin-2275.51%
EBIT Margin-2330.62%
Analyst Forecast
The average price target for Rani Therapeutics Holdings is $6.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.75
Price Target Upside658.43% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast306.42%
EPS Growth Forecast70.84%